Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted non-qualified stock options for 191,000 shares to two newly hired employees at an exercise price of $3.98 per share. The company is strengthening its commercial leadership team and advancing its registrational program for azenosertib, a first-in-class WEE1 inhibitor, in platinum-resistant ovarian cancer treatment.

06/01/2026, 5:00 PM • GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted 26,000 non-qualified stock options to a newly hired employee on May 1, 2026, with an exercise price of $4.09 per share under the 2022 Inducement Plan. The options have a 10-year term and vest over four years, subject to continued employment.

05/01/2026, 5:30 PM • GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted non-qualified stock options to purchase 36,000 shares to two newly hired employees on April 1, 2026, with an exercise price of $2.57 per share. The options vest over four years under the company's 2022 Inducement Plan.

04/01/2026, 5:00 PM • GlobeNewswire

Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026

The oncology landscape is experiencing rapid regulatory advancement as precision medicine and genomics expand significantly. Multiple biotech companies are advancing cancer therapies toward accelerated FDA approvals in 2026, with the precision medicine market projected to grow from $138.67 billion in 2026 to $537.17 billion by 2035. Key developments include Oncolytics' pelareorep showing strong response rates in anal cancer, CG Oncology's Phase 3 trial ahead of schedule, Zentalis advancing azenosertib in ovarian cancer, ArriVent initiating a pivotal Phase 3 study for firmonertinib, and PDS Biotechnology gaining FDA alignment on trial endpoints.

01/12/2026, 10:35 AM • Benzinga

Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell

Incyclix Bio, a cell cycle control company, appointed Dr. Kimberly Blackwell to its Board of Directors. Dr. Blackwell brings over 20 years of drug development experience and expertise in oncology research, particularly in breast cancer treatment.

12/17/2025, 9:00 AM • GlobeNewswire

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted non-qualified stock options to purchase 381,000 shares of common stock to six newly hired employees under their 2022 Employment Inducement Incentive Award Plan.

09/02/2025, 5:00 PM • GlobeNewswire

Zentalis (ZNTL) Q2 Loss Narrows 70%

Zentalis Pharmaceuticals reported a narrower net loss in Q2 2025, reducing operating expenses by 44.7% while maintaining cash reserves to support operations through late 2027. The company continues developing azenosertib, a cancer therapy, with ongoing clinical trials for platinum-resistant ovarian cancer.

08/06/2025, 8:28 PM • The Motley Fool

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals granted 14,000 stock options to a newly hired employee under its 2022 Employment Inducement Incentive Award Plan, with options vesting over four years at an exercise price of $1.19 per share.

07/01/2025, 5:00 PM • GlobeNewswire